Mesenchymal Stem Cells

Clinical trials employing cultured human bone marrow mesenchymal stem cells (hBM‐MSCs) have demonstrated the presence of significant inter‐donor variability in biological functions and clinical efficacy.

Bronchopulmonary dysplasia (BPD) is the most common cause of morbidity and mortality in extremely premature neonates, and, unfortunately, current therapies for BPD are limited.

While mesenchymal stem cells (MSC) release ATP as an extracellular signaling molecule in response to mechanical and diverse other stimuli, the underlying mechanisms remain largely unknown.

Osteoarthritis (OA) patients suffer from irreversible and challenging to repair defects in the cartilage; however, mesenchymal stem cell (MSC)-based cartilage regeneration may represent an exciting approach if we can inhibit the excessive chondrocyte hypertrophy observed in the inflammatory intra‐articular conditions of OA.

In a new STEM CELLS Translational Medicine article, researchers from the laboratory

A research team led by Sajit Augustine (Western University, Ontario, Canada) recently performed a systematic review and network me

While attaining a critical number of in vitro expanded progenitor cells provides the key driving force in a cell‐based regenerative construct, the standard expansion protocols currently employed affect the initial cellular phenotype due to a focus on rapid expansion and not maintenance of progenitor potential.

A new study from the lab of Cesar V. Borlongan (University of South Florida, Tampa, Florida, USA) studied mesenchymal stem cells (MSCs) as a means to treat ischemic stroke with the recognition that critical translational gaps in stem cell transplant dose, route, and timing after stroke exist while acknowledging the need for a solid safety profiles for MSCs.

A team of researchers led by Mengfei Yu and Huiming Wang (Zhejiang University, Hangzhou, China) recently investigated KLF2 as a novel in vitro marker for mesenchymal stem cells (MSCs) to investigate osteogenesis and angiogenesis following the interaction between KLF2+ MSCs and endothelial cells (ECs). Zhou et al.

Renal fibrosis treatment strategies have previously employed the intravascular administration of stem cells.